- Home
- STOK vs LASR Comparison
STOK vs LASR Comparison
Compare STOK & LASR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STOK
- LASR
- Stock Information
- Founded
- STOK 2014
- LASR 2000
- Country
- STOK United States
- LASR United States
- Employees
- STOK N/A
- LASR N/A
- Industry
- STOK Biotechnology: Pharmaceutical Preparations
- LASR Semiconductors
- Sector
- STOK Health Care
- LASR Technology
- Exchange
- STOK Nasdaq
- LASR Nasdaq
- Market Cap
- STOK 556.7M
- LASR N/A
- IPO Year
- STOK 2019
- LASR 2018
- Fundamental
- Price
- STOK $7.21
- LASR $7.95
- Analyst Decision
- STOK Strong Buy
- LASR Strong Buy
- Analyst Count
- STOK 8
- LASR 4
- Target Price
- STOK $23.83
- LASR $15.13
- AVG Volume (30 Days)
- STOK 868.5K
- LASR 460.1K
- Earning Date
- STOK 03-18-2025
- LASR 05-01-2025
- Dividend Yield
- STOK N/A
- LASR N/A
- EPS Growth
- STOK N/A
- LASR N/A
- EPS
- STOK N/A
- LASR N/A
- Revenue
- STOK $36,555,000.00
- LASR $198,548,000.00
- Revenue This Year
- STOK N/A
- LASR $7.88
- Revenue Next Year
- STOK N/A
- LASR $12.43
- P/E Ratio
- STOK N/A
- LASR N/A
- Revenue Growth
- STOK 316.34
- LASR N/A
- 52 Week Low
- STOK $7.06
- LASR $7.84
- 52 Week High
- STOK $17.58
- LASR $14.73
- Technical
- Relative Strength Index (RSI)
- STOK 34.49
- LASR 30.94
- Support Level
- STOK $7.18
- LASR $8.34
- Resistance Level
- STOK $8.45
- LASR $8.84
- Average True Range (ATR)
- STOK 0.60
- LASR 0.38
- MACD
- STOK -0.04
- LASR -0.03
- Stochastic Oscillator
- STOK 7.59
- LASR 6.94
About STOK Stoke Therapeutics Inc.
Stoke Therapeutics Inc is engaged in addressing the underlying causes of severe diseases by upregulating protein expression with RNA-based medicines. Using its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, it is developing antisense oligonucleotides (ASOs) to selectively restore protein levels. Its first compound, STK-001, is in clinical testing for the treatment of Dravet syndrome, a severe and progressive genetic epilepsy. The company primarily operates in the U.S.